MaaT Pharma, the clinical-stage biotechnology company renowned for its pioneering work in microbiome-driven immunotherapies, has announced compelling preclinical findings for its latest therapy candidate, MaaT034.

Scheduled for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting in Chicago, MaaT034 represents a significant advance in cancer treatment, aiming to enhance patient responses to existing immunotherapies.

Developed using MaaT Pharma’s innovative MET-C platform, MaaT034 is a synthetic microbiome therapy designed without reliance on human donors, optimizing consistency and scalability. Key preclinical studies conducted on germ-free mice have demonstrated that MaaT034 successfully colonizes the gut, resulting in prolonged beneficial effects. Crucially, it has shown potential in significantly enhancing the anti-tumor effects of immune checkpoint inhibitors like anti-PD-1.

The therapy also promotes the generation of vital microbial metabolites, such as short-chain fatty acids, secondary bile acids, and tryptophan derivatives. These substances are known to improve gut barrier functions and modulate immune responses, suggesting substantial benefits in oncology treatments.

CEO Hervé Affagard highlighted the strategic importance of MaaT034, emphasizing its role in broadening therapeutic potential across various cancer types. MaaT Pharma’s ongoing clinical trials, including the Phase 2a PICASSO study using MaaT013 for melanoma, underline its commitment to innovation and patient outcomes. These promising results position MaaT034 as a potentially transformative therapy, expanding the frontiers of cancer immunotherapy through microbiome modulation.